Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study

Authors: Longxiang Su, Bingchao Han, Changting Liu, Liling Liang, Zhaoxu Jiang, Jie Deng, Peng Yan, Yanhong Jia, Dan Feng, Lixin Xie

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

The purpose of this study was to explore the diagnostic value of soluble triggering receptor expressed on myeloid cells 1 (sTREM-1), procalcitonin (PCT), and C-reactive protein (CRP) serum levels for differentiating sepsis from SIRS, identifying new fever caused by bacteremia, and assessing prognosis when new fever occurred.

Methods

We enrolled 144 intensive care unit (ICU) patients: 60 with systemic inflammatory response syndrome (SIRS) and 84 with sepsis complicated by new fever at more than 48 h after ICU admission. Serum sTREM-1, PCT, and CRP levels were measured on the day of admission and at the occurrence of new fever (>38.3°C) during hospitalization. Based on the blood culture results, the patients were divided into a blood culture-positive bacteremia group (33 patients) and blood culture-negative group (51 patients). Based on 28-day survival, all patients, both blood culture-positive and -negative, were further divided into survivor and nonsurvivor groups.

Results

On ICU day 1, the sepsis group had higher serum sTREM-1, PCT, and CRP levels compared with the SIRS group (P <0.05). The areas under the curve (AUC) for these indicators were 0.868 (95% CI, 0.798–0.938), 0.729 (95% CI, 0.637–0.821), and 0.679 (95% CI, 0.578–0.771), respectively. With 108.9 pg/ml as the cut-off point for serum sTREM-1, sensitivity was 0.83 and specificity was 0.81. There was no statistically significant difference in serum sTREM-1 or PCT levels between the blood culture-positive and -negative bacteremia groups with ICU-acquired new fever. However, the nonsurvivors in the blood culture-positive bacteremia group had higher levels of serum sTREM-1 and PCT (P <0.05), with a prognostic AUC for serum sTREM-1 of 0.868 (95% CI, 0.740–0.997).

Conclusions

Serum sTREM-1, PCT, and CRP levels each have a role in the early diagnosis of sepsis. Serum sTREM-1, with the highest sensitivity and specificity of all indicators studied, is especially notable. sTREM-1, PCT, and CRP levels are of no use in determining new fever caused by bacteremia in ICU patients, but sTREM-1 levels reflect the prognosis of bacteremia.

Trial registration

ClinicalTrial.gov identifier NCT01410578
Appendix
Available only for authorised users
Literature
1.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001, 29 (7): 1303-1310. 10.1097/00003246-200107000-00002.CrossRefPubMed
2.
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004, 39 (3): 309-317. 10.1086/421946.CrossRefPubMed
3.
Bates DW, Sands K, Miller E, Lanken PN, Hibberd PL, Graman PS, Schwartz JS, Kahn K, Snydman DR, Parsonnet J, et al: Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group. J Infect Dis. 1997, 176 (6): 1538-1551. 10.1086/514153.CrossRefPubMed
4.
Bossink AW, Groeneveld J, Hack CE, Thijs LG: Prediction of mortality in febrile medical patients: How useful are systemic inflammatory response syndrome and sepsis criteria?. Chest. 1998, 113 (6): 1533-1541. 10.1378/chest.113.6.1533.CrossRefPubMed
5.
Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB: The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997, 24 (4): 584-602.CrossRefPubMed
6.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001, 345 (19): 1368-1377. 10.1056/NEJMoa010307.CrossRefPubMed
7.
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004, 32 (3): 858-873. 10.1097/01.CCM.0000117317.18092.E4.CrossRefPubMed
8.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992, 101 (6): 1644-1655. 10.1378/chest.101.6.1644.CrossRefPubMed
9.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003, 31 (4): 1250-1256. 10.1097/01.CCM.0000050454.01978.3B.CrossRefPubMed
10.
Livermore DM JD, Reacher M, et al: CDC definitions of nosocomial infections. APIC infection control and applied epidemiology:principles and practice. 1996, , , A-1-A-20-
11.
Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008, 36 (5): 309-332. 10.1016/j.ajic.2008.03.002.CrossRefPubMed
12.
De La Rosa GD, Valencia ML, Arango CM, Gomez CI, Garcia A, Ospina S, Osorno S, Henao A, Jaimes FA: Toward an operative diagnosis in sepsis: a latent class approach. BMC Infect Dis. 2008, 8: 18-10.1186/1471-2334-8-18.CrossRefPubMedPubMedCentral
13.
Jaimes F, Arango C, Ruiz G, Cuervo J, Botero J, Velez G, Upegui N, Machado F: Predicting bacteremia at the bedside. Clin Infect Dis. 2004, 38 (3): 357-362. 10.1086/380967.CrossRefPubMed
14.
15.
O'Grady NP, Barie PS, Bartlett J, Bleck T, Garvey G, Jacobi J, Linden P, Maki DG, Nam M, Pasculle W, et al: Practice parameters for evaluating new fever in critically ill adult patients. Crit Care Med. 1998, 26 (2): 392-408. 10.1097/00003246-199802000-00046.CrossRefPubMed
16.
O'Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC, Linden P, Maki DG, Nierman D, Pasculle W, et al: Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med. 2008, 36 (4): 1330-1349. 10.1097/CCM.0b013e318169eda9.CrossRefPubMed
17.
Dimopoulos G, Falagas ME: Approach to the febrile patient in the ICU. Infect Dis Clin North Am. 2009, 23 (3): 471-484. 10.1016/j.idc.2009.04.001.CrossRefPubMed
18.
Towns ML, Jarvis WR, Hsueh PR: Guidelines on blood cultures. J Microbiol Immunol Infect. 2010, 43 (4): 347-349. 10.1016/S1684-1182(10)60054-0.CrossRefPubMed
19.
Richter SS, Beekmann SE, Croco JL, Diekema DJ, Koontz FP, Pfaller MA, Doern GV: Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm. J Clin Microbiol. 2002, 40 (7): 2437-2444. 10.1128/JCM.40.7.2437-2444.2002.CrossRefPubMedPubMedCentral
20.
Schuetz P, Mueller B, Trampuz A: Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection. 2007, 35 (5): 352-355. 10.1007/s15010-007-7065-0.CrossRefPubMed
21.
Gibot S, Kolopp-Sarda MN, Bene MC, Cravoisy A, Levy B, Faure GC, Bollaert PE: Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med. 2004, 141 (1): 9-15.CrossRefPubMed
22.
Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE: Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004, 350 (5): 451-458. 10.1056/NEJMoa031544.CrossRefPubMed
23.
Liu CL, Hsieh WY, Wu CL, Kuo HT, Lu YT: Triggering receptor expressed on myeloid cells-1 in pleural effusions: a marker of inflammatory disease. Respir Med. 2007, 101 (5): 903-909. 10.1016/j.rmed.2006.09.021.CrossRefPubMed
24.
Collins CE, La DT, Yang HT, Massin F, Gibot S, Faure G, Stohl W: Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. Ann Rheum Dis. 2009, 68 (11): 1768-1774. 10.1136/ard.2008.089557.CrossRefPubMed
25.
Determann RM, Weisfelt M, de Gans J, van der Ende A, Schultz MJ, van de Beek D: Soluble triggering receptor expressed on myeloid cells 1: a biomarker for bacterial meningitis. Intensive Care Med. 2006, 32 (8): 1243-1247. 10.1007/s00134-006-0240-4.CrossRefPubMed
26.
Kusanovic JP, Romero R, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Vaisbuch E, Erez O, Gotsch F, Than NG, Edwin SS, et al: Amniotic fluid sTREM-1 in normal pregnancy, spontaneous parturition at term and preterm, and intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med. 2010, 23 (1): 34-47. 10.3109/14767050903009248.CrossRefPubMedPubMedCentral
27.
Determann RM, van Till JW, van Ruler O, van Veen SQ, Schultz MJ, Boermeester MA: sTREM-1 is a potential useful biomarker for exclusion of ongoing infection in patients with secondary peritonitis. Cytokine. 2009, 46 (1): 36-42. 10.1016/j.cyto.2008.12.006.CrossRefPubMed
28.
Su LX, Feng L, Zhang J, Xiao YJ, Jia YH, Yan P, Feng D, Xie LX: Diagnostic value of urine sTREM-1 for sepsis and relevant acute kidney injuries: a prospective study. Crit Care. 2011, 15 (5): R250-10.1186/cc10508.CrossRefPubMedPubMedCentral
29.
Zhang J, She D, Feng D, Jia Y, Xie L: Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infect Dis. 2011, 11: 53-10.1186/1471-2334-11-53.CrossRefPubMedPubMedCentral
30.
Gibot S, Cravoisy A, Kolopp-Sarda MN, Bene MC, Faure G, Bollaert PE, Levy B: Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med. 2005, 33 (4): 792-796. 10.1097/01.CCM.0000159089.16462.4A.CrossRefPubMed
31.
Oczenski W, Fitzgerald RD, Schwarz S: Procalcitonin: a new parameter for the diagnosis of bacterial infection in the peri-operative period. Eur J Anaesthesiol. 1998, 15 (2): 202-209.CrossRefPubMed
32.
Christ-Crain M, Muller B: Procalcitonin in bacterial infections–hype, hope, more or less?. Swiss Med Wkly. 2005, 135 (31–32): 451-460.PubMed
33.
Bloos F, Marshall JC, Dellinger RP, Vincent JL, Gutierrez G, Rivers E, Balk RA, Laterre PF, Angus DC, Reinhart K, et al: Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care. 2011, 15 (2): R88-10.1186/cc10087.CrossRefPubMedPubMedCentral
34.
Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, Mouktaroudi M, Pantelidou I, Adamis G, Atmatzidis S, Chrisofos M, Evangelopoulou V, Frantzeskaki F, et al: Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect. 2011, 77 (1): 58-63. 10.1016/j.jhin.2010.07.026.CrossRefPubMed
35.
Ruiz-Laiglesia FJ, Torrubia-Perez C, Amiguet-Garcia JA, Fiteni-Mera I: Value of C-reactive protein for detecting bacteremia in febrile patients. Presse Med. 1996, 25 (24): 1105-1108.PubMed
36.
Povoa P: C-reactive protein: a valuable marker of sepsis. Intensive Care Med. 2002, 28 (3): 235-243. 10.1007/s00134-002-1209-6.CrossRefPubMed
37.
Wyllie DH, Bowler IC, Peto TE: Bacteraemia prediction in emergency medical admissions: role of C reactive protein. J Clin Pathol. 2005, 58 (4): 352-356. 10.1136/jcp.2004.022293.CrossRefPubMedPubMedCentral
38.
Lee CC, Hong MY, Lee NY, Chen PL, Chang CM, Ko WC: Pitfalls in using serum C-reactive protein to predict bacteremia in febrile adults in the ED. Am J Emerg Med. 2012, 30 (4): 562-569. 10.1016/j.ajem.2011.02.012.CrossRefPubMed
39.
Rivera-Chavez FA, Minei JP: Soluble triggering receptor expressed on myeloid cells-1 is an early marker of infection in the surgical intensive care unit. Surg Infect (Larchmt). 2009, 10 (5): 435-439. 10.1089/sur.2009.030.CrossRef
40.
Porfyridis I, Plachouras D, Karagianni V, Kotanidou A, Papiris SA, Giamarellou H, Giamarellos-Bourboulis EJ: Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infect Dis. 2010, 10: 286-10.1186/1471-2334-10-286.CrossRefPubMedPubMedCentral
41.
Jiyong J, Tiancha H, Wei C, Huahao S: Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-analysis. Intensive Care Med. 2009, 35 (4): 587-595. 10.1007/s00134-008-1333-z.CrossRefPubMed
42.
Latour-Perez J, Alcala-Lopez A, Garcia-Garcia MA, Sanchez-Hernandez JF, Abad-Terrado C, Viedma-Contreras JA, Masia M, Gonzalez-Tejera M, Arizo-Leon D, Porcar MJ, et al: Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. Clin Biochem. 2010, 43 (9): 720-724. 10.1016/j.clinbiochem.2010.03.001.CrossRefPubMed
43.
Bopp C, Hofer S, Bouchon A, Zimmermann JB, Martin E, Weigand MA: Soluble TREM-1 is not suitable for distinguishing between systemic inflammatory response syndrome and sepsis survivors and nonsurvivors in the early stage of acute inflammation. Eur J Anaesthesiol. 2009, 26 (6): 504-507. 10.1097/EJA.0b013e328329afca.CrossRefPubMed
44.
Adib-Conquy M, Monchi M, Goulenok C, Laurent I, Thuong M, Cavaillon JM, Adrie C: Increased plasma levels of soluble triggering receptor expressed on myeloid cells 1 and procalcitonin after cardiac surgery and cardiac arrest without infection. Shock. 2007, 28 (4): 406-410. 10.1097/shk.0b013e3180488154.CrossRefPubMed
45.
Barati M, Bashar FR, Shahrami R, Zadeh MH, Taher MT, Nojomi M: Soluble triggering receptor expressed on myeloid cells 1 and the diagnosis of sepsis. J Crit Care. 2010, 25 (2): 362 e361-366-CrossRef
46.
Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, Larsen K: Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007, 11 (2): R38-10.1186/cc5723.CrossRefPubMedPubMedCentral
47.
Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM: Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol. 2011, 135 (2): 182-189. 10.1309/AJCP1MFYINQLECV2.CrossRefPubMed
48.
Kim MH, Lim G, Kang SY, Lee WI, Suh JT, Lee HJ: Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J. 2011, 52 (2): 276-281. 10.3349/ymj.2011.52.2.276.CrossRefPubMedPubMedCentral
49.
Lai CC, Tan CK, Chen SY, Wang CY, Liu WL, Hou CC, Hsueh PR: Diagnostic performance of procalcitonin for bacteremia in patients with bacterial infection at the emergency department. J Infect. 2010, 61 (6): 512-515. 10.1016/j.jinf.2010.10.005.CrossRefPubMed
50.
Blijlevens NM, Donnelly JP, Meis JF, De Keizer MH, De Pauw BE: Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol. 2000, 7 (6): 889-892.PubMedPubMedCentral
51.
Ruiz-Gonzalez A, Esquerda A, Falguera M, Abdulghani N, Cabezas P, Bielsa S, Porcel JM: Triggering receptor (TREM-1) expressed on myeloid cells predicts bacteremia better than clinical variables in community-acquired pneumonia. Respirology. , 16 (2): 321-325.
52.
Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA : the journal of the American Medical Association. 1995, 273 (2): 117-123.PubMed
53.
Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, et al: Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997, 278 (3): 234-240. 10.1001/jama.1997.03550030074038.CrossRefPubMed
Metadata
Title
Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study
Authors
Longxiang Su
Bingchao Han
Changting Liu
Liling Liang
Zhaoxu Jiang
Jie Deng
Peng Yan
Yanhong Jia
Dan Feng
Lixin Xie
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-157

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue

Research article

Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial

Research article

HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes

Research article

Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review

Correspondence

“Blind periods” in screening for toxoplasmosis in pregnancy in Austria – a debate

Research article

Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico

Research article

Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits